


# Correction to Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B *Streptococcus* Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide

Alberto Nilo, Irene Passalacqua, Monica Fabbrini, Martin Allan, Aimee Usera, Filippo Carboni, Barbara Brogioni, Alfredo Pezzicoli, Jennifer Cobb, Maria Rosaria Romano, Immaculada Margarit, Qi-Ying Hu, Francesco Berti, and Roberto Adamo\*

*Bioconjugate Chem.* **2015**, *26* (8), 1839–1849. DOI: [10.1021/acs.bioconjchem.5b00365](https://doi.org/10.1021/acs.bioconjchem.5b00365)

The original article contained an error in Figure 1 and an omission for Scheme 1. Dr. Sebastien Vidal (University of Lyon, CNRS) is kindly acknowledged for having identified the mistakes in the original paper.



**Figure 1.** Chemical structure of PSV.

**Scheme 1.** Synthesis of the modified PSV. For chemical modification is sialic acid, see also Avci, F. Y., Li, X., and Kasper, D. L. (2012) Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccines. *Nat. Protoc.* *7*, 2180–2192; and Kima, J. S., Laskowich, E. R., Michon, F., Kaiser, R. E., and Arumugham, R. G. (2006) Monitoring activation sites on polysaccharides by GC–MS. *Anal. Biochem.* *358*, 136–142.